836643-56-2

Upstream product

• 693-25-4 n-pentylmagnesium bromide 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 69739-34-0 t-butyldimethylsiyl triflate 
• 71434-62-3 (+/-)-p-bromophenyl-1-hexanol 

Downstream Products

• 836643-54-0 4-(4-(1-(t-butyldimethylsilyloxy)hexyl)phenyl)-2-cyclopenten-1-ol 
• 890845-18-8 C₄₁H₆₆O₅Si₂ 
• 927831-57-0 [4-[1-(tert-butyldimethylsilanyloxy)hexyl]phenyl]methanol 
• 951401-85-7 C₃₇H₆₆O₅Si₂ 
• 890845-45-1 3-[3-((1R,2S,3R)-3-(tert-butyl-dimethyl-silanyloxy)-2-{4-[1-(tert-butyl-dimethyl-silanyloxy)-hexyl]-phenyl}-5-oxo-cyclopentylmethyl)-phenyl]-propionic acid methyl ester 
• 1073241-71-0 C₂₃H₃₉NO₃Si 
• 836643-57-3 3-(4-(1-(t-butyldimethylsilyloxy)hexyl)phenyl)-2-(7-(4-(methoxy)benzyloxy)heptyl)cyclopentan-1-ol 
• 836643-58-4 3-(4-(1-(t-butyldimethylsilyloxy)hexyl)phenyl)-2-(7-(hydroxy)heptyl)cyclopentan-1-ol 
• 148436-63-9 AH 13205 
• 148436-63-9 7-{(1S,2S)-2-[4-(1-Hydroxy-hexyl)-phenyl]-5-oxo-cyclopentyl}-heptanoic acid 
• 836643-55-1 Acetic acid (1S,4S)-4-{4-[1-(tert-butyl-dimethyl-silanyloxy)-hexyl]-phenyl}-cyclopent-2-enyl ester 
• 960205-66-7 C₂₂H₃₇NO₄Si 

Relevant academic research and scientific papers

New reagent system for attaining high regio- and stereoselectivities in allylic displacement of 4-cyclopentene-1,3-diol monoacetate with aryl- and alkenylmagnesium bromides

(Chemical Equation Presented) Low regioselectivity of RMgBr (R = aryl, alkenyl) in the CuCN-catalyzed reaction with 4-cyclopentene-1,3-diol monoacetate is improved by addition of LiCl or MgCl2 to a similar extent as previously obtained with RMg

THERAPEUTIC SUBSTITUTED CYCLOPENTANES

Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.

Therapeutic Substituted Cyclopentanes

Therapeutic compounds are disclosed herein. ???????????

SULFONAMIDES

The present invention provides R, R1, R2, R3, X, c, d, e, f, g, x, y, a, b, z and n are defined in the specification. These compounds are useful in lowering IOP and/or treating glaucoma or providing neuroprotection to the

12-ARYL PROSTAGLANDIN ANALOGS

Compounds comprising the formula (I) are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the ω-chain comprises a substituted phenyl, wherein at least one substituent